1
|
Abstract
Thalidomide and its derivatives are powerful cancer therapeutics that are among the best-understood molecular glue degraders (MGDs). These drugs selectively reprogram the E3 ubiquitin ligase cereblon (CRBN) to commit target proteins for degradation by the ubiquitin-proteasome system. MGDs create novel recognition interfaces on the surface of the E3 ligase that engage in induced protein-protein interactions with neosubstrates. Molecular insight into their mechanism of action opens exciting opportunities to engage a plethora of targets through a specific recognition motif, the G-loop. Our analysis shows that current CRBN-based MGDs can in principle recognize over 2,500 proteins in the human proteome that contain a G-loop. We review recent advances in tuning the specificity between CRBN and its MGD-induced neosubstrates and deduce a set of simple rules that govern these interactions. We conclude that rational MGD design efforts will enable selective degradation of many more proteins, expanding this therapeutic modality to more disease areas.
Collapse
Affiliation(s)
| | | | | | | | - Nicolas H Thomä
- Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland;
| |
Collapse
|
2
|
Gavory G, Ghandi M, d’Alessandro AC, Bonenfant D, Chicas A, Delobel F, Demarco B, Flohr A, King C, Laine AL, Massafra V, Narayan R, Osmont A, Ottaviani G, Peck D, Pessa S, Rubin N, Ryckmans T, Schillo M, Singh A, Tortoioli S, Vigil D, Zarayskiy V, Castle J, Janku F, Wallace O, Buonamici S, Fasching B. Abstract 3929: Identification of MRT-2359 a potent, selective and orally bioavailable GSPT1-directed molecular glue degrader (MGD) for the treatment of cancers with Myc-induced translational addiction. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-3929] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Myc transcription factors are well-established drivers of human cancers. However, despite being amongst the most frequently mutated, translocated and overexpressed oncogenes, no therapy targeting the Myc family members directly has been developed to date. To sustain uncontrolled cell proliferation and tumor growth, Myc-driven cancers are known to be addicted to protein translation. This addiction creates a dependency on critical components of the translational machinery providing in turn a unique opportunity for therapeutic intervention. We hypothesized that targeting the translational termination factor GSPT1, a key regulator of protein synthesis, would constitute a vulnerability for Myc-driven tumors. GSPT1 contains a well-defined degron allowing for the recruitment of the E3 ligase cereblon (CRBN) and subsequent proteasomal degradation in the presence of molecular glue degraders. Herein we describe a novel orally bioavailable GSPT1-directed small molecule degrader MRT-2359, which has been rationally designed and optimized to selectively induce apoptosis in translationally addicted cells. MRT-2359 promotes complex formation between CRBN and GSPT1 and potently induces GSPT1 degradation in a CRBN- and degron-dependent manner. The high selectivity of MRT-2359 was subsequently demonstrated by the lack of activity in cells expressing a non-degradable GSPT1 mutant. Although MRT-2359 degrades GSPT1 in all the cell lines tested, profiling in a large panel of cancer lines revealed profound and preferential antiproliferative activity in Myc-driven cell lines, such as high N-Myc expressing non-small cell lung cancer (NSCLC) lines and high L-Myc expressing small cell lung cancer (SCLC) lines. In the Myc-driven cells, degradation of GSPT1 led to translational repression as manifested by a global shift from polysomes to monosomes resulting in the reduction of a subset of proteins as assessed by quantitative proteomics. In particular, N- or L-Myc protein levels decreased and as a consequence the known Myc target genes were downregulated at the mRNA level. Despite the robust degradation of GSPT1, no marked effect was observed in low N-Myc lines, confirming the selective activity of our GSPT1 degrader in Myc-driven lung cancers. Finally, oral administration of MRT-2359 in high N-Myc NSCLC xenografts and PDXs led to complete intratumoral GSPT1 degradation and concomitant decrease in N-Myc protein levels, resulting in tumor regression. In contrast, MRT-2359 had limited or no activity in low N-Myc NSCLC models, further corroborating the selective vulnerability of Myc-driven tumors to GSPT1 degradation. Together these data support the therapeutic potential of GSPT1-directed MGDs in Myc-driven solid tumors addicted to the protein translation machinery and warrant rapid evaluation towards the clinic.
Citation Format: Gerald Gavory, Mahmoud Ghandi, Anne-Cecile d’Alessandro, Debora Bonenfant, Agustin Chicas, Frederic Delobel, Brad Demarco, Alexander Flohr, Christopher King, Anne-Laure Laine, Vittoria Massafra, Rajiv Narayan, Arnaud Osmont, Giorgio Ottaviani, Dave Peck, Sarah Pessa, Nooreen Rubin, Thomas Ryckmans, Martin Schillo, Ambika Singh, Simone Tortoioli, Dominico Vigil, Vladislav Zarayskiy, John Castle, Filip Janku, Owen Wallace, Silvia Buonamici, Bernhard Fasching. Identification of MRT-2359 a potent, selective and orally bioavailable GSPT1-directed molecular glue degrader (MGD) for the treatment of cancers with Myc-induced translational addiction [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3929.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Dave Peck
- 2Monte Rosa Therapeutics, Boston, MA
| | | | | | | | | | | | | | | | | | - John Castle
- 1Monte Rosa Therapeutics, Basel, Switzerland
| | | | | | | | | |
Collapse
|
3
|
Gavory G, Fasching B, Bonenfant D, Sadok A, Singh A, Schillo M, Massafra V, d’Alessandro AC, Castle J, Ghandi M, Chicas A, Delobel F, Flohr A, Ottaviani G, Ryckmans T, Laine AL, Eidam O, Wang H, Bernett I, Chan L, Gorrini C, Roumiliotis T, Choudhary J, LeBihan YV, Cabry M, Stubbs M, Burke R, Van Montfort R, Caldwell J, Chopra R, Collins I, Buonamici S. Abstract LBA004: Identification of GSPT1-directed molecular glue degrader (MGD) for the treatment of Myc-driven breast cancer. Mol Cancer Ther 2021. [DOI: 10.1158/1535-7163.targ-21-lba004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The Myc family of transcription factors is a well-established driver of human cancers. However, despite being amongst the most frequently mutated, translocated and overexpressed oncogenes, no therapy directly targeting the Myc family members has been developed to date. Abnormal activation of Myc results in uncontrolled cell growth that is associated with high translational output and ramp up of the protein translational machinery. This creates a dependency to protein translation and in turn represents a potential therapeutic vulnerability for Myc-driven tumors. Based on these considerations, we hypothesized that targeting the translational termination factor GSPT1, a key player of protein synthesis, may constitute a vulnerability for Myc-driven tumors. Using our proprietary Quantitative and Engineered Elimination of Neosubstrates (QuEENTM) platform we characterized and explored the known G-loop degron in GSPT1 that renders it amenable to cereblon-induced degradation by molecular glue degraders (MGDs). We rationally designed and subsequently screened a proprietary library of cereblon-binding small molecules, including GSPT1-directed MGDs, in human mammary epithelial cells (HMECs) expressing doxycycline-inducible c-Myc. Doxycycline treatment led to sustained c-Myc expression and as a consequence to the induction of key biomarkers of enhanced protein translation, such as phospho 4EBP1 (p4EBP1). We identified MRT-048 as a potent and highly selective GSPT1 degrader and demonstrated its ability to induce cell death in Myc-driven HMEC cells whilst sparing control cells (EC50 0.64 μM vs 30 μM respectively). This confirmed the selective vulnerability of Myc-driven cell growth to GSPT1 degradation. In follow-up studies, we confirmed the correlation between p4EBP1 as biomarker of Myc-activation and sensitivity to MRT-048 in a large panel of breast cancer cell lines. Moreover, MRT-048 treatment of animals xenografted with breast cancer cells induced tumor regression and was associated with complete GSPT1 degradation. Mechanistically, we observed that GSPT1 degradation induced by MRT-048 led to inhibition of genes regulated by Myc and ribosomal stalling at stop codons of several mRNAs. Additionally, polysome profiling of cancer cells treated with MRT-048 was associated with a global reduction of the intensities of the polysome peaks and concomitant increase in the monosome peaks as previously observed in GSPT1 knockdown experiments, suggesting that GSPT1 degradation by our MGD molecules affects both the termination and initiation stages of protein translation. We believe these data support the therapeutic potential of GSPT1-directed MGDs in Myc-driven tumors dependent on protein translation machinery.
Citation Format: Gerald Gavory, Bernhard Fasching, Debora Bonenfant, Amine Sadok, Ambika Singh, Martin Schillo, Vittoria Massafra, Anne-Cecile d’Alessandro, John Castle, Mahmoud Ghandi, Agustin Chicas, Frederic Delobel, Alexander Flohr, Giorgio Ottaviani, Thomas Ryckmans, Anne-Laure Laine, Oliv Eidam, Hannah Wang, Ilona Bernett, Laura Chan, Chiara Gorrini, Theo Roumiliotis, Jyoti Choudhary, Yann-Vai LeBihan, Marc Cabry, Mark Stubbs, Rosemary Burke, Rob Van Montfort, John Caldwell, Rajesh Chopra, Ian Collins, Silvia Buonamici. Identification of GSPT1-directed molecular glue degrader (MGD) for the treatment of Myc-driven breast cancer [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2021 Oct 7-10. Philadelphia (PA): AACR; Mol Cancer Ther 2021;20(12 Suppl):Abstract nr LBA004.
Collapse
Affiliation(s)
| | | | | | - Amine Sadok
- 1Monte Rosa Therapeutics AG, Basel, Switzerland,
| | - Ambika Singh
- 1Monte Rosa Therapeutics AG, Basel, Switzerland,
| | | | | | | | - John Castle
- 1Monte Rosa Therapeutics AG, Basel, Switzerland,
| | | | | | | | | | | | | | | | - Oliv Eidam
- 3Ridgeline Discovery, Basel, Switzerland,
| | - Hannah Wang
- 4The Institute of Cancer Research, London, United Kingdom,
| | - Ilona Bernett
- 4The Institute of Cancer Research, London, United Kingdom,
| | - Laura Chan
- 4The Institute of Cancer Research, London, United Kingdom,
| | - Chiara Gorrini
- 4The Institute of Cancer Research, London, United Kingdom,
| | | | | | | | - Marc Cabry
- 4The Institute of Cancer Research, London, United Kingdom,
| | - Mark Stubbs
- 4The Institute of Cancer Research, London, United Kingdom,
| | - Rosemary Burke
- 4The Institute of Cancer Research, London, United Kingdom,
| | | | - John Caldwell
- 4The Institute of Cancer Research, London, United Kingdom,
| | | | - Ian Collins
- 4The Institute of Cancer Research, London, United Kingdom,
| | | |
Collapse
|
4
|
Dal Molin M, Selchow P, Schäfle D, Tschumi A, Ryckmans T, Laage-Witt S, Sander P. Identification of novel scaffolds targeting Mycobacterium tuberculosis. J Mol Med (Berl) 2019; 97:1601-1613. [PMID: 31728550 DOI: 10.1007/s00109-019-01840-7] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2019] [Revised: 09/13/2019] [Accepted: 09/26/2019] [Indexed: 10/25/2022]
Abstract
Drug resistance in Mycobacterium tuberculosis is relentlessly progressing while only a handful of novel drug candidates are developed. Here we describe a GFP-based high-throughput screening of 386,496 diverse compounds to identify putative tuberculosis drug candidates. In an exploratory analysis of the model organism M. bovis BCG and M. smegmatis and the subsequent screening of the main library, we identified 6354 compounds with anti-mycobacterial activity. These hit compounds were predominantly selective for mycobacteria while dozens had activity in the low μM range. We tested toxicity against the human monocyte/macrophage cell line THP-1 and elaborated activity against M. tuberculosis growing in liquid broth, under unique conditions such as non-replicating persistence or inhibition of M. tuberculosis residing in macrophages. Finally, spontaneous compound-resistant M. tuberculosis mutants were selected and subsequently analyzed by whole genome sequencing. In addition to compounds targeting the well-described proteins Pks13 and MmpL3, we identified two novel scaffolds targeting the bifunctional guanosine pentaphosphate synthetase/ polyribonucleotide nucleotidyltransferase GpsI, or interacting with the aminopeptidase PepB, a probable pro-drug activator. KEY MESSAGES: A newly identified scaffold targets the bifunctional enzyme GpsI. The aminopeptidase PepB is interacting with a second novel scaffold. Phenotypic screenings regularly identify novel compounds targeting Pks13 and MmpL3.
Collapse
Affiliation(s)
- Michael Dal Molin
- Institut für Medizinische Mikrobiologie, Universität Zürich, 8006, Zürich, Switzerland
| | - Petra Selchow
- Institut für Medizinische Mikrobiologie, Universität Zürich, 8006, Zürich, Switzerland
| | - Daniel Schäfle
- Institut für Medizinische Mikrobiologie, Universität Zürich, 8006, Zürich, Switzerland
| | - Andreas Tschumi
- Roche Pharma Research and Early Development, Infectious Diseases, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, 4070, Basel, Switzerland
| | - Thomas Ryckmans
- Roche Pharma Research and Early Development, Infectious Diseases, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, 4070, Basel, Switzerland
| | - Stephan Laage-Witt
- Roche Pharma Research and Early Development, Infectious Diseases, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, 4070, Basel, Switzerland
| | - Peter Sander
- Institut für Medizinische Mikrobiologie, Universität Zürich, 8006, Zürich, Switzerland. .,Nationales Zentrum für Mykobakterien, 8006, Zürich, Switzerland.
| |
Collapse
|
5
|
Sommer R, Rox K, Wagner S, Hauck D, Henrikus SS, Newsad S, Arnold T, Ryckmans T, Brönstrup M, Imberty A, Varrot A, Hartmann RW, Titz A. Anti-biofilm Agents against Pseudomonas aeruginosa: A Structure-Activity Relationship Study of C-Glycosidic LecB Inhibitors. J Med Chem 2019; 62:9201-9216. [PMID: 31553873 PMCID: PMC6873108 DOI: 10.1021/acs.jmedchem.9b01120] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Biofilm formation is a key mechanism of antimicrobial resistance. We have recently reported two classes of orally bioavailable C-glycosidic inhibitors of the Pseudomonas aeruginosa lectin LecB with antibiofilm activity. They proved efficient in target binding, were metabolically stable, nontoxic, selective, and potent in inhibiting formation of bacterial biofilm. Here, we designed and synthesized six new carboxamides and 24 new sulfonamides for a detailed structure-activity relationship for two clinically representative LecB variants. Sulfonamides generally showed higher inhibition compared to carboxamides, which was rationalized based on crystal structure analyses. Substitutions at the thiophenesulfonamide increased binding through extensive contacts with a lipophilic protein patch. These metabolically stable compounds showed a further increase in potency toward the target and in biofilm inhibition assays. In general, we established the structure-activity relationship for these promising antibiofilm agents and showed that modification of the sulfonamide residue bears future optimization potential.
Collapse
Affiliation(s)
- Roman Sommer
- Chemical Biology of Carbohydrates , Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research , D-66123 Saarbrücken , Germany.,Deutsches Zentrum für Infektionsforschung (DZIF) , Standort Hannover, D-38124 Braunschweig , Germany
| | - Katharina Rox
- Deutsches Zentrum für Infektionsforschung (DZIF) , Standort Hannover, D-38124 Braunschweig , Germany.,Chemical Biology , Helmholtz Centre for Infection Research , D-38124 Braunschweig , Germany
| | - Stefanie Wagner
- Chemical Biology of Carbohydrates , Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research , D-66123 Saarbrücken , Germany.,Deutsches Zentrum für Infektionsforschung (DZIF) , Standort Hannover, D-38124 Braunschweig , Germany
| | - Dirk Hauck
- Chemical Biology of Carbohydrates , Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research , D-66123 Saarbrücken , Germany.,Deutsches Zentrum für Infektionsforschung (DZIF) , Standort Hannover, D-38124 Braunschweig , Germany
| | - Sarah S Henrikus
- Chemical Biology of Carbohydrates , Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research , D-66123 Saarbrücken , Germany.,Deutsches Zentrum für Infektionsforschung (DZIF) , Standort Hannover, D-38124 Braunschweig , Germany.,Department of Pharmacy , Saarland University , D-66123 Saarbrücken , Germany
| | - Shelby Newsad
- Chemical Biology of Carbohydrates , Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research , D-66123 Saarbrücken , Germany.,Deutsches Zentrum für Infektionsforschung (DZIF) , Standort Hannover, D-38124 Braunschweig , Germany
| | - Tatjana Arnold
- Deutsches Zentrum für Infektionsforschung (DZIF) , Standort Hannover, D-38124 Braunschweig , Germany.,Chemical Biology , Helmholtz Centre for Infection Research , D-38124 Braunschweig , Germany
| | - Thomas Ryckmans
- Roche Pharmaceutical Research and Early Development , Roche Innovation Center Basel , CH-4070 Basel , Switzerland
| | - Mark Brönstrup
- Deutsches Zentrum für Infektionsforschung (DZIF) , Standort Hannover, D-38124 Braunschweig , Germany.,Chemical Biology , Helmholtz Centre for Infection Research , D-38124 Braunschweig , Germany
| | - Anne Imberty
- Univ. Grenoble Alpes , CNRS, CERMAV , F-38000 Grenoble , France
| | | | - Rolf W Hartmann
- Deutsches Zentrum für Infektionsforschung (DZIF) , Standort Hannover, D-38124 Braunschweig , Germany.,Department of Pharmacy , Saarland University , D-66123 Saarbrücken , Germany.,Drug Design and Development , Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research , D-66123 Saarbrücken , Germany
| | - Alexander Titz
- Chemical Biology of Carbohydrates , Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research , D-66123 Saarbrücken , Germany.,Deutsches Zentrum für Infektionsforschung (DZIF) , Standort Hannover, D-38124 Braunschweig , Germany.,Department of Pharmacy , Saarland University , D-66123 Saarbrücken , Germany
| |
Collapse
|
6
|
Sommer R, Wagner S, Rox K, Varrot A, Hauck D, Wamhoff EC, Schreiber J, Ryckmans T, Brunner T, Rademacher C, Hartmann RW, Brönstrup M, Imberty A, Titz A. Glycomimetic, Orally Bioavailable LecB Inhibitors Block Biofilm Formation of Pseudomonas aeruginosa. J Am Chem Soc 2018; 140:2537-2545. [PMID: 29272578 DOI: 10.1021/jacs.7b11133] [Citation(s) in RCA: 73] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The opportunistic Gram-negative bacterium Pseudomonas aeruginosa is a leading pathogen for infections of immuno-compromised patients and those suffering from cystic fibrosis. Its ability to switch from planktonic life to aggregates, forming the so-called biofilms, is a front-line mechanism of antimicrobial resistance. The bacterial carbohydrate-binding protein LecB is an integral component and necessary for biofilm formation. Here, we report a new class of drug-like low molecular weight inhibitors of the lectin LecB with nanomolar affinities and excellent receptor binding kinetics and thermodynamics. This class of glycomimetic inhibitors efficiently blocked biofilm formation of P. aeruginosa in vitro while the natural monovalent carbohydrate ligands failed. Furthermore, excellent selectivity and pharmacokinetic properties were achieved. Notably, two compounds showed good oral bioavailability, and high compound concentrations in plasma and urine were achieved in vivo.
Collapse
Affiliation(s)
- Roman Sommer
- Chemical Biology of Carbohydrates and ‡Drug Design and Development, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) , D-66123 Saarbrücken, Germany.,Deutsches Zentrum für Infektionsforschung (DZIF) , Standort Hannover-Braunschweig, Germany
| | - Stefanie Wagner
- Chemical Biology of Carbohydrates and ‡Drug Design and Development, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) , D-66123 Saarbrücken, Germany.,Deutsches Zentrum für Infektionsforschung (DZIF) , Standort Hannover-Braunschweig, Germany
| | - Katharina Rox
- Deutsches Zentrum für Infektionsforschung (DZIF) , Standort Hannover-Braunschweig, Germany
| | - Annabelle Varrot
- Univ. Grenoble Alpes , CNRS, Centre de Recherche sur les Macromolécules Végétales (CERMAV), 38000 Grenoble, France
| | - Dirk Hauck
- Chemical Biology of Carbohydrates and ‡Drug Design and Development, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) , D-66123 Saarbrücken, Germany.,Deutsches Zentrum für Infektionsforschung (DZIF) , Standort Hannover-Braunschweig, Germany
| | - Eike-Christian Wamhoff
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces , D-14424 Potsdam, Germany.,Department of Biology, Chemistry and Pharmacy, Freie Universität Berlin , D-14195 Berlin, Germany
| | - Janine Schreiber
- Deutsches Zentrum für Infektionsforschung (DZIF) , Standort Hannover-Braunschweig, Germany
| | - Thomas Ryckmans
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel , CH-4070 Basel, Switzerland
| | - Thomas Brunner
- Biochemical Pharmacology, Department of Biology, University of Konstanz , D-78457 Konstanz, Germany
| | - Christoph Rademacher
- Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces , D-14424 Potsdam, Germany.,Department of Biology, Chemistry and Pharmacy, Freie Universität Berlin , D-14195 Berlin, Germany
| | - Rolf W Hartmann
- Deutsches Zentrum für Infektionsforschung (DZIF) , Standort Hannover-Braunschweig, Germany.,Department of Pharmacy, Saarland University , D-66123 Saarbrücken, Germany
| | - Mark Brönstrup
- Deutsches Zentrum für Infektionsforschung (DZIF) , Standort Hannover-Braunschweig, Germany
| | - Anne Imberty
- Univ. Grenoble Alpes , CNRS, Centre de Recherche sur les Macromolécules Végétales (CERMAV), 38000 Grenoble, France
| | - Alexander Titz
- Chemical Biology of Carbohydrates and ‡Drug Design and Development, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) , D-66123 Saarbrücken, Germany.,Deutsches Zentrum für Infektionsforschung (DZIF) , Standort Hannover-Braunschweig, Germany.,Department of Pharmacy, Saarland University , D-66123 Saarbrücken, Germany
| |
Collapse
|
7
|
Storer RI, Pike A, Swain NA, Alexandrou AJ, Bechle BM, Blakemore DC, Brown AD, Castle NA, Corbett MS, Flanagan NJ, Fengas D, Johnson MS, Jones LH, Marron BE, Payne CE, Printzenhoff D, Rawson DJ, Rose CR, Ryckmans T, Sun J, Theile JW, Torella R, Tseng E, Warmus JS. Highly potent and selective NaV1.7 inhibitors for use as intravenous agents and chemical probes. Bioorg Med Chem Lett 2017; 27:4805-4811. [DOI: 10.1016/j.bmcl.2017.09.056] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2017] [Revised: 09/17/2017] [Accepted: 09/27/2017] [Indexed: 01/04/2023]
|
8
|
Skerratt SE, Andrews M, Bagal SK, Bilsland J, Brown D, Bungay PJ, Cole S, Gibson KR, Jones R, Morao I, Nedderman A, Omoto K, Robinson C, Ryckmans T, Skinner K, Stupple P, Waldron G. The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain. J Med Chem 2016; 59:10084-10099. [PMID: 27766865 DOI: 10.1021/acs.jmedchem.6b00850] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
The neurotrophin family of growth factors, comprised of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4), is implicated in the physiology of chronic pain. Given the clinical efficacy of anti-NGF monoclonal antibody (mAb) therapies, there is significant interest in the development of small molecule modulators of neurotrophin activity. Neurotrophins signal through the tropomyosin related kinase (Trk) family of tyrosine kinase receptors, hence Trk kinase inhibition represents a potentially "druggable" point of intervention. To deliver the safety profile required for chronic, nonlife threatening pain indications, highly kinase-selective Trk inhibitors with minimal brain availability are sought. Herein we describe how the use of SBDD, 2D QSAR models, and matched molecular pair data in compound design enabled the delivery of the highly potent, kinase-selective, and peripherally restricted clinical candidate PF-06273340.
Collapse
Affiliation(s)
- Sarah E Skerratt
- Pfizer Global Research & Development , The Portway Building, Granta Park, Great Abington, Cambridge, CB21 6GS, U.K
| | - Mark Andrews
- Pfizer Global Research & Development , Ramsgate Road, Sandwich CT13 9NJ, U.K
| | - Sharan K Bagal
- Pfizer Global Research & Development , The Portway Building, Granta Park, Great Abington, Cambridge, CB21 6GS, U.K
| | - James Bilsland
- Pfizer Global Research & Development , The Portway Building, Granta Park, Great Abington, Cambridge, CB21 6GS, U.K
| | - David Brown
- Pfizer Global Research & Development , Ramsgate Road, Sandwich CT13 9NJ, U.K
| | - Peter J Bungay
- Pfizer Global Research & Development , The Portway Building, Granta Park, Great Abington, Cambridge, CB21 6GS, U.K
| | - Susan Cole
- Pfizer Global Research & Development , Ramsgate Road, Sandwich CT13 9NJ, U.K
| | - Karl R Gibson
- Pfizer Global Research & Development , Ramsgate Road, Sandwich CT13 9NJ, U.K
| | - Russell Jones
- Pfizer Global Research & Development , Ramsgate Road, Sandwich CT13 9NJ, U.K
| | - Inaki Morao
- Pfizer Global Research & Development , Ramsgate Road, Sandwich CT13 9NJ, U.K
| | - Angus Nedderman
- Pfizer Global Research & Development , Ramsgate Road, Sandwich CT13 9NJ, U.K
| | - Kiyoyuki Omoto
- Pfizer Global Research & Development , The Portway Building, Granta Park, Great Abington, Cambridge, CB21 6GS, U.K
| | - Colin Robinson
- Pfizer Global Research & Development , Ramsgate Road, Sandwich CT13 9NJ, U.K
| | - Thomas Ryckmans
- Pfizer Global Research & Development , Ramsgate Road, Sandwich CT13 9NJ, U.K
| | - Kimberly Skinner
- Pfizer Global Research & Development , Ramsgate Road, Sandwich CT13 9NJ, U.K
| | - Paul Stupple
- Pfizer Global Research & Development , Ramsgate Road, Sandwich CT13 9NJ, U.K
| | - Gareth Waldron
- Pfizer Global Research & Development , The Portway Building, Granta Park, Great Abington, Cambridge, CB21 6GS, U.K
| |
Collapse
|
9
|
Pryde DC, Marron B, West CG, Reister S, Amato G, Yoger K, Padilla K, Turner J, Swain NA, Cox PJ, Skerratt SE, Ryckmans T, Blakemore DC, Warmus J, Gerlach AC. The discovery of a potent series of carboxamide TRPA1 antagonists. Med Chem Commun 2016. [DOI: 10.1039/c6md00387g] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Potent and selective carboxamide TRPA1 antagonists were identified by high throughput screening, with efficacy demonstrated in a topical inflammation model.
Collapse
Affiliation(s)
- D. C. Pryde
- Pfizer Worldwide Medicinal Chemistry
- Neuroscience and Pain Research Unit
- Great Abington
- UK
| | | | | | | | | | | | | | - J. Turner
- Neuroscience and Pain Research Unit
- Great Abington
- UK
| | - N. A. Swain
- Pfizer Worldwide Medicinal Chemistry
- Neuroscience and Pain Research Unit
- Great Abington
- UK
| | - P. J. Cox
- Neuroscience and Pain Research Unit
- Great Abington
- UK
| | - S. E. Skerratt
- Pfizer Worldwide Medicinal Chemistry
- Neuroscience and Pain Research Unit
- Great Abington
- UK
| | - T. Ryckmans
- Pfizer Worldwide Medicinal Chemistry
- Sandwich
- UK
| | - D. C. Blakemore
- Pfizer Worldwide Medicinal Chemistry
- Neuroscience and Pain Research Unit
- Great Abington
- UK
| | - J. Warmus
- Pfizer Worldwide Medicinal Chemistry
- Neuroscience and Pain Research Unit
- Groton
- USA
| | | |
Collapse
|
10
|
Kilty I, Green MP, Bell AS, Brown DG, Dodd PG, Hewson C, Hughes SJ, Phillips C, Ryckmans T, Smith RT, van Hoorn WP, Cohen P, Jones LH. TAK1 inhibition in the DFG-out conformation. Chem Biol Drug Des 2014; 82:500-5. [PMID: 23745990 DOI: 10.1111/cbdd.12169] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2013] [Revised: 05/28/2013] [Accepted: 06/03/2013] [Indexed: 12/20/2022]
Abstract
The first example of an inhibitor of the kinase TAK1 that binds in the DFG-out conformation is disclosed. These preliminary studies used kinase-targeted screening and structure-based drug design to create a molecule with dual pharmacological inhibition of p38 and TAK1 that demonstrated significant activity in a cell-based, anti-inflammatory assay.
Collapse
Affiliation(s)
- Iain Kilty
- Pfizer World Wide Research and Development, Ramsgate Road, Sandwich, CT13 9NJ, UK; BioTherapeutics Research and Development, Pfizer, Cambridge, MA, 02140, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Ryckmans T. Case Studies in Modern Drug Discovery and Development. Edited by Xianhai Huang and Robert G. Aslanian. ChemMedChem 2013. [DOI: 10.1002/cmdc.201300001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
12
|
Mills JEJ, Brown AD, Ryckmans T, Miller DC, Skerratt SE, Barker CM, Bunnage ME. SAR mining and its application to the design of TRPA1 antagonists. Med Chem Commun 2012. [DOI: 10.1039/c1md00213a] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
13
|
Wijeyesekera A, Clarke PA, Bictash M, Brown IJ, Fidock M, Ryckmans T, Yap IKS, Chan Q, Stamler J, Elliott P, Holmes E, Nicholson JK. Quantitative UPLC-MS/MS analysis of the gut microbial co-metabolites phenylacetylglutamine, 4-cresyl sulphate and hippurate in human urine: INTERMAP Study. Anal Methods 2012; 4:65-72. [PMID: 23946767 PMCID: PMC3740387 DOI: 10.1039/c1ay05427a] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/17/2023]
Abstract
The role of the gut microbiome in human health, and non-invasive measurement of gut dysbiosis are of increasing clinical interest. New high-throughput methods are required for the rapid measurement of gut microbial metabolites and to establish reference ranges in human populations. We used ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) -- positive and negative electrospray ionization modes, multiple reaction monitoring transitions -- to simultaneously measure three urinary metabolites (phenylacetylglutamine, 4-cresyl sulphate and hippurate) that are potential biomarkers of gut function, among multi-ethnic US men and women aged 40-59 from the INTERMAP epidemiologic study (n = 2000, two timed 24-hr urine collections/person). Metabolite concentrations were quantified via stable isotope labeled internal standards. The assay was linear in the ranges 1ng/mL (lower limit of quantification) to 1000ng/mL (phenylacetylglutamine and 4-cresyl sulfate) and 3ng/mL to 3000ng/mL (hippurate). These quantitative data provide new urinary reference ranges for population-based human samples: mean (standard deviation) 24-hr urinary excretion for phenylacetylglutamine was: 1283.0 (751.7) μmol/24-hr (men), 1145.9 (635.5) μmol/24-hr (women); for 4-cresyl sulphate, 1002.5 (737.1) μmol/24-hr (men), 1031.8 (687.9) μmol/24-hr (women); for hippurate, 6284.6 (4008.1) μmol/24-hr (men), 4793.0 (3293.3) μmol/24-hr (women). Metabolic profiling by UPLC-MS/MS in a large sample of free-living individuals has provided new data on urinary reference ranges for three urinary microbial co-metabolites, and demonstrates the applicability of this approach to epidemiological investigations.
Collapse
Affiliation(s)
- Anisha Wijeyesekera
- Section of Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, W2 1PG, UK
| | - Philip A. Clarke
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK
| | - Magda Bictash
- Section of Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK
| | - Ian J. Brown
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, W2 1PG, UK
| | - Mark Fidock
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK
| | - Thomas Ryckmans
- Pfizer Global Research and Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK
| | - Ivan K. S. Yap
- Section of Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, W2 1PG, UK
| | - Queenie Chan
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, W2 1PG, UK
| | - Jeremiah Stamler
- Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL60611, USA
| | - Paul Elliott
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, W2 1PG, UK
- MRC-HPA Centre for Environment and Health, Imperial College London, W2 1PG, UK
| | - Elaine Holmes
- Section of Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK
- MRC-HPA Centre for Environment and Health, Imperial College London, W2 1PG, UK
| | - Jeremy K. Nicholson
- Section of Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK
- MRC-HPA Centre for Environment and Health, Imperial College London, W2 1PG, UK
- Corresponding Author:
| |
Collapse
|
14
|
Nakagawa S, Bainbridge KA, Butcher K, Ellis D, Klute W, Ryckmans T. Application of Barluenga Boronic Coupling (BBC) to the Parallel Synthesis of Drug-like and Drug Fragment-like Molecules. ChemMedChem 2011; 7:233-6. [DOI: 10.1002/cmdc.201100339] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2011] [Revised: 10/20/2011] [Indexed: 11/07/2022]
|
15
|
Beal DM, Bryans JS, Johnson PS, Newman J, Pasquinet C, Peakman TM, Ryckmans T, Underwood TJ, Wheeler S. Preparation of triazolobenzodiazepine derivatives as Vasopressin V1a antagonists. Tetrahedron Lett 2011. [DOI: 10.1016/j.tetlet.2011.08.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
16
|
Ryckmans T, Aubdool AA, Bodkin JV, Cox P, Brain SD, Dupont T, Fairman E, Hashizume Y, Ishii N, Kato T, Kitching L, Newman J, Omoto K, Rawson D, Strover J. Design and pharmacological evaluation of PF-4840154, a non-electrophilic reference agonist of the TrpA1 channel. Bioorg Med Chem Lett 2011; 21:4857-9. [DOI: 10.1016/j.bmcl.2011.06.035] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2011] [Revised: 06/07/2011] [Accepted: 06/09/2011] [Indexed: 11/15/2022]
|
17
|
Ryckmans T. Modulation of the vasopressin system for the treatment of CNS diseases. Curr Opin Drug Discov Devel 2010; 13:538-547. [PMID: 20812145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
Vasopressin (also known as arginine vasopressin [AVP]) is a small cyclic peptide that acts at the V1a, V1b and V2 GPCRs to regulate a wide range of physiological functions, including vasoconstriction, smooth muscle contractility, response to stress, and excretion of water and sodium via the kidney. The potential therapeutic applications of AVP receptor ligands have prompted significant interest in this target within the pharmaceutical research community, and several small-molecule drugs targeting the AVP receptor have reached the market, mainly for cardiovascular indications. The development of AVP receptor modulators for the treatment of CNS indications has proven more challenging, and is the focus of this review. The regulatory role of AVP on the hypothalamic-pituitary-adrenal (HPA) axis suggests potential uses for AVP receptor modulators in various CNS indications, including depression, anxiety and post-traumatic stress disorder. Several clinical trials of V1a and V1b receptor antagonists in CNS indications have been conducted, but none of these drugs have reached the market. In recent years, the discovery of the key role of AVP in modulating complex social behaviors has provided a unique opportunity to understand the physiological mechanisms of social interactions. Ultimately, the ongoing research in this field may enable the development of treatments to alleviate the social deficits associated with conditions such as autism and schizophrenia. Given the large unmet medical need in these areas, a renewed interest in the field of CNS-penetrant AVP receptors modulators is expected.
Collapse
Affiliation(s)
- Thomas Ryckmans
- Pfizer Worldwide Research and Development, 500.2.190 Ramsgate Road ipc 432, Sandwich, Kent, CT13 9NJ, UK.
| |
Collapse
|
18
|
Wakenhut F, Allan GA, Fish PV, Fray MJ, Harrison AC, McCoy R, Phillips SC, Ryckmans T, Stobie A, Westbrook D, Westbrook SL, Whitlock GA. Corrigendum to “N-[(3S)-Pyrrolidin-3-yl]benzamides as novel dual serotonin and noradrenaline reuptake inhibitors: Impact of small structural modifications on P-gp recognition and CNS penetration” [Bioorg. Med. Chem. Lett. 19 (2009) 5078]. Bioorg Med Chem Lett 2010. [DOI: 10.1016/j.bmcl.2009.11.096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
19
|
Fish PV, Mackenny M, Bish G, Buxton T, Cave R, Drouard D, Hoople D, Jessiman A, Miller D, Pasquinet C, Patel B, Reeves K, Ryckmans T, Skerten M, Wakenhut F. Enantioselective synthesis of (R)- and (S)-N-Boc-morpholine-2-carboxylic acids by enzyme-catalyzed kinetic resolution: application to the synthesis of reboxetine analogs. Tetrahedron Lett 2009. [DOI: 10.1016/j.tetlet.2008.11.025] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
20
|
Fish PV, Barta NS, Gray DLF, Ryckmans T, Stobie A, Wakenhut F, Whitlock GA. Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity. Bioorg Med Chem Lett 2008; 18:4355-9. [PMID: 18621528 DOI: 10.1016/j.bmcl.2008.06.071] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2008] [Accepted: 06/23/2008] [Indexed: 01/16/2023]
Abstract
Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine are disclosed as a new series of noradrenaline reuptake inhibitors (NRI). Carboxamide 9e, carbamate 11b and sulfonamide 13a were identified as potent NRIs with excellent selectivity over SRI and DRI, good in vitro metabolic stability and weak CYP inhibition. Carbamate 11b demonstrated superior transit performance in MDCK-mdr1 cell lines with minimal P-gp efflux which was attributed to reduced HBA capacity of the carbamate group. Evaluation in vivo, in rat microdialysis experiments, showed 11b increased noradrenaline levels by 400% confirming good CNS penetration.
Collapse
Affiliation(s)
- Paul V Fish
- Discovery Chemistry, Pfizer Global Research and Development, Sandwich Laboratories, Sandwich, Kent CT13 9NJ, UK.
| | | | | | | | | | | | | |
Collapse
|
21
|
Fish PV, Deur C, Gan X, Greene K, Hoople D, Mackenny M, Para KS, Reeves K, Ryckmans T, Stiff C, Stobie A, Wakenhut F, Whitlock GA. Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition. Bioorg Med Chem Lett 2008; 18:2562-6. [DOI: 10.1016/j.bmcl.2008.03.050] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2008] [Revised: 03/14/2008] [Accepted: 03/16/2008] [Indexed: 01/16/2023]
|
22
|
Fish PV, Ryckmans T, Stobie A, Wakenhut F. [4-(Phenoxy)pyridin-3-yl]methylamines: A new class of selective noradrenaline reuptake inhibitors. Bioorg Med Chem Lett 2008; 18:1795-8. [DOI: 10.1016/j.bmcl.2008.02.036] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2008] [Revised: 02/11/2008] [Accepted: 02/12/2008] [Indexed: 01/16/2023]
|
23
|
Abstract
The total synthesis of the polyhydroxylated macrolide (+)-aspicilin 5 is described using as a key step a highly diastereoselective allylation of aldehyde 6 with the uniquely functionalized allylstannane 1. (+)-Aspicilin is obtained in 18 steps and 10% overall yield. [structure: see text]
Collapse
Affiliation(s)
- Christophe Dubost
- Université Catholique de Louvain, Département de Chimie, 1 Place Louis Pasteur, B-1348 Louvain La Neuve, Belgium
| | | | | |
Collapse
|
24
|
Genicot C, Christophe B, Collart P, Gillard M, Goossens L, Hénichart JP, Lassoie MA, Moureau F, Neuwels M, Nicolas JM, Pasau P, Quéré L, Ryckmans T, Stiernet F, Taverne T, Van Keulen BJ. Discovery of orally bioavailable NK1 receptor antagonists. Bioorg Med Chem Lett 2003; 13:437-42. [PMID: 12565946 DOI: 10.1016/s0960-894x(02)00956-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Benzyloxyphenethylpiperazines are a new class of high affinity NK1 receptor antagonists. Oral bioavailability and selectivity can be fine tuned by the nature of the substituents on the basic nitrogen atom. Addition of substituents with a carboxylic acid group led to very selective and orally active NK1 antagonists free of interaction with L-type calcium channels.
Collapse
Affiliation(s)
- C Genicot
- Chemistry Department, UCB Pharma, Chemin du Foriest, B-1420, Braine-l'Alleud, Belgium.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Ryckmans T, Berton O, Grimée R, Kogej T, Lamberty Y, Pasau P, Talaga P, Genicot C. Dual NK(1) antagonists--serotonin reuptake inhibitors as potential antidepressants. Part 2: SAR and activity of benzyloxyphenethyl piperazine derivatives. Bioorg Med Chem Lett 2002; 12:3195-8. [PMID: 12372532 DOI: 10.1016/s0960-894x(02)00563-2] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The synthesis, structure-affinity relationship and activity of benzyloxyphenethyl piperazine derivatives combining NK(1) antagonism and serotonin reuptake inhibition is described. Compound 7u was shown to be active in animal models of 5-HT reuptake inhibition and central NK(1) receptor blockade, and was demonstrated to be orally active in an integrated model sensitive to both mechanisms. This class of compounds potentially represents a new generation of antidepressants.
Collapse
Affiliation(s)
- Thomas Ryckmans
- Chemical Research, R&D, UCB Pharma SA, Chemin du Foriest, B-1420, Braine-l'Alleud, Belgium.
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Ryckmans T, Balançon L, Berton O, Genicot C, Lamberty Y, Lallemand B, Pasau P, Pirlot N, Quéré L, Talaga P. First dual NK(1) antagonists-serotonin reuptake inhibitors: synthesis and SAR of a new class of potential antidepressants. Bioorg Med Chem Lett 2002; 12:261-4. [PMID: 11755367 DOI: 10.1016/s0960-894x(01)00727-2] [Citation(s) in RCA: 61] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Compounds combining NK(1) antagonism and serotonin reuptake inhibition are described, and potentially represent a new generation of antidepressants. Compound 24 displays good affinities for both the NK(1) receptor and the serotonin reuptake site (32 and 25 nM, respectively).
Collapse
Affiliation(s)
- Thomas Ryckmans
- Chemical Research, R&D, UCB Pharma SA, Chemin du Foriest, B-1420 Braine-l'Alleud, Belgium.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
|
28
|
Rousselle D, Ryckmans T, Viehe HG. Benzimidazolo-diazepines from 1,3-dienes and arenediazocyanides through a 1,3,4-tri-aza-Cope rerrangement. Tetrahedron 1992. [DOI: 10.1016/s0040-4020(01)89022-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|